Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
44.63
-0.98 (-2.15%)
At close: Jul 31, 2026, 4:00 PM EDT
45.01
+0.38 (0.85%)
After-hours: Jul 31, 2026, 7:45 PM EDT
Supernus Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Supernus Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $63.5. The average 1-year stock price forecast is 42.28% higher than the current stock price, while the lowest is $55 (+23.24%) and the highest is $67 (+50.12%).
Price Target: $63.5 (+42.28%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Supernus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $66 | Buy | Reiterates | $66 | +47.88% | Jul 27, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $63 | Buy | Maintains | $63 | +41.16% | Jul 13, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $65 | Buy | Maintains | $65 | +45.64% | Jul 10, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $63 → $67 | Buy | Maintains | $63 → $67 | +50.12% | Jul 9, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $55 | Hold | Maintains | $55 | +23.24% | May 6, 2026 |
Financial Forecast
Revenue This Year
867.18M
from 718.95M
Increased by 20.62%
Revenue Next Year
1.02B
from 867.18M
Increased by 17.96%
EPS This Year
2.49
from 2.40
Increased by 3.82%
EPS Next Year
4.34
from 2.49
Increased by 74.66%
EPS and Forward PE are based on non-GAAP adjusted numbers.